ZITHROMAX
Drug
PFIZER INC.
Total Payments
$1.8M
Transactions
6
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $3,750 | 1 | 1 |
| 2019 | $789,149 | 2 | 0 |
| 2017 | $988,041 | 3 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 4 | 99.6% |
| Consulting Fee | $7,500 | 2 | 0.4% |
Payments by Type
Research
$1.8M
4 transactions
General
$7,500
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| THE ACUTE EFFECTS OF AZITHROMYCIN USE ON CARDIOVASCULAR MORTALITY AS COMPARED WITH AMOXICILLIN | PFIZER INC. | $1.8M | 0 |
Top Doctors Receiving Payments for ZITHROMAX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Antioch, CA | $1.8M | 4 |
| , MD | Pulmonary Disease | San Antonio, TX | $7,500 | 2 |
Ad
Manufacturing Companies
- PFIZER INC. $1.8M
Product Information
- Type Drug
- Total Payments $1.8M
- Total Doctors 1
- Transactions 6
About ZITHROMAX
ZITHROMAX is a drug associated with $1.8M in payments to 1 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2020. In 2020, $3,750 was paid across 1 transactions to 1 doctors.
The most common payment nature for ZITHROMAX is "Unspecified" ($1.8M, 99.6% of total).
ZITHROMAX is associated with 1 research study, including "THE ACUTE EFFECTS OF AZITHROMYCIN USE ON CARDIOVASCULAR MORTALITY AS COMPARED WITH AMOXICILLIN" ($1.8M).